Brief: Akari Therapeutics Announces First Patient To Complete Course Of Treatment In The Phase III Part A Clinical Trial Of Investigational Nomacopan
07/07/2022 13:03
July 7 (Reuters) - Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS ANNOUNCES FIRST PATIENT TO COMPLETE
COURSE OF
TREATMENT IN THE PHASE III PART A CLINICAL TRIAL OF
INVESTIGATIONAL NOMACOPAN IN PEDIATRIC HEMATOPOIETIC STEM CELL
TRANSPLANT-RELATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA)
Source text for Eikon: ID:nGNE2pyRl4
Further company coverage: AKTX.O
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics